In conclusion, we have demonstrated that measuring AFP to detect HCC can improve overall and cancer-specific mortalities in patients with chronic liver disorders, even after correcting for lead times due to AFP screening. The gene discussed is AFP; the disease is hepatocellular carcinoma.